Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Access Bio Inc

Access Bio is dedicated to the prevention and early diagnosis of infectious diseases through research, development, a... read more Featured Products: More products

Download Mobile App




Rapid Diagnostic Test for The Detection of G6PD Deficiency Evaluated

By LabMedica International staff writers
Posted on 07 Jan 2020
To reduce the risk of drug-induced hemolysis, all patients should be tested for glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PDd) prior to prescribing primaquine (PQ)-based radical cure for the treatment of vivax malaria.

The gold standard method for measuring G6PD activity is quantitative spectrophotometry, but this method is expensive and requires laboratory facilities that are often unavailable in malaria-endemic communities, especially in remote areas. More...
The fluorescent spot test (FST) is a qualitative alternative; however, it also requires laboratory infrastructure and extensive training for reliable interpretation.

An international team of scientists led by the Charles Darwin University (Darwin, Australia) carried out a systematic review and individual patient meta-analysis assessed the utility of a qualitative lateral flow assay from CareStart Screening test for G6PD deficiency (CSG, Access Bio/CareStart, Somerset, NJ, USA) for the diagnosis of G6PDd compared to the gold standard spectrophotometry using kits from Trinity Biotech PLC (Wicklow, Ireland).

All of the studies included were undertaken between 2014 and 2018. Six studies were conducted in Southeast Asia, one in Africa, and one in the Americas. In total, three studies (four countries, 2,845 participants) assessed G6PD status from capillary blood and three from venous blood (three countries, 2,066 participants). In one study, CSG and spectrophotometry were performed on both venous and capillary samples, and in one study CSG was performed on both venous and capillary samples; however, spectrophotometry was only performed on capillary blood.

A total of 5,815 individual participant data (IPD) were available, of which 5,777 results (99.3%) were considered for analysis, including data from 3,095 (53.6%) females. Overall, the CSG had a pooled sensitivity of 0.96 and a specificity of 0.95. When the prevalence of G6PDd was varied from 5% to 30%, the unconditional negative predictive value (NPV) was 0.99, with a positive likelihood ratio (LR+) and an LR− of 18.23 and 0.05, respectively. Performance was significantly better in males compared to females but did not differ significantly between samples collected from capillary or venous blood.

The authors concluded that the CSG performed well at the 30% threshold. Its high NPV suggests that the test is suitable to guide PQ treatment, and the high LR+ and low LR− render the test suitable to confirm and exclude G6PDd. In a comparison between Trinity spectrophotometry kits, considered for this analysis, and another spectrophotometry kit (Pointe Scientific, Canton, MI, USA), both assays showed a very good correlation. The study was published on December 13, 2019 in the journal Public Library of Science Medicine.

Related Links:
Charles Darwin University
Access Bio
Trinity Biotech PLC
Pointe Scientific



New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Collection and Transport System
PurSafe Plus®
New
8-Channel Pipette
SAPPHIRE 20–300 µL
New
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.